head of the Sanofi Pasteur vaccines division at the French drugmaker. "Welcoming Origimm within Sanofi expands our area of expertise by bringing extensive know-how in the field of skin microbiome ...

Sanofi reported third-quarter earnings and sales that beat analysts’ expectations, boosted by earlier-than-anticipated ...

To receive full access to Campaign's content including: Unrestricted access to all The Information and The Knowledge content Access to Campaign's in-depth features and coveted reports including ...

Sanofi reported a 25% boost in sales for its vaccines division during the third quarter, helped by earlier-than-anticipated orders of its flu shots as well as rising revenue from Beyfortus ...

Vaccines sales rose a currency-adjusted 25.5% to 3.8 billion euros in the quarter, ahead of a 3.2 billion euro analyst consensus. Sanofi is nearing a sale of a 50% stake in its consumer unit ...

Investing.com -- Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales ...

Sanofi’s third-quarter results showed the company’s pharma and vaccines businesses grew faster and were more profitable than its consumer-health unit Opella.